News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,192 Results
Type
Article (2438)
Company Profile (39)
Press Release (35715)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (14119)
Career Advice (77)
Deals (2078)
Drug Delivery (9)
Drug Development (4100)
Employer Resources (10)
FDA (431)
Job Trends (763)
News (20134)
Policy (1052)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (144)
Allergies (6)
Alliances (3471)
ALS (4)
Alzheimer's disease (45)
Antibody-drug conjugate (ADC) (14)
Approvals (432)
Artificial intelligence (11)
Autoimmune disease (3)
Automation (1)
Bankruptcy (12)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (19)
Cancer (139)
Cardiovascular disease (5)
Career advice (64)
Career pathing (1)
CAR-T (15)
Cell therapy (43)
Cervical cancer (2)
Clinical research (3175)
Collaboration (94)
Compensation (48)
COVID-19 (180)
CRISPR (7)
C-suite (27)
Cystic fibrosis (2)
Data (113)
Denatured (3)
Depression (3)
Diabetes (10)
Diagnostics (464)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (15)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4235)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6025)
Executive appointments (96)
FDA (477)
Featured Employer (3)
Funding (77)
Gene editing (14)
Gene therapy (18)
GLP-1 (60)
Government (149)
Healthcare (704)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (16)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (988)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (4)
Layoffs (37)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (19)
MASH (4)
Medical device (307)
Medtech (307)
Mergers & acquisitions (1159)
Metabolic disorders (34)
Multiple sclerosis (7)
Neurodegenerative disease (9)
Neuropsychiatric disorders (3)
Neuroscience (90)
NextGen: Class of 2025 (353)
Non-profit (153)
Northern California (359)
Now hiring (4)
Obesity (16)
Opinion (16)
Ovarian cancer (10)
Pain (9)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (2)
Patents (22)
Patient recruitment (4)
Peanut (1)
People (5660)
Pharmaceutical (5)
Phase I (1372)
Phase II (1591)
Phase III (846)
Pipeline (74)
Policy (12)
Postmarket research (30)
Preclinical (593)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (22)
Real estate (420)
Recruiting (5)
Regulatory (803)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (25)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (354)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (490)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1726)
Vaccines (28)
Venture capitalists (8)
Weight loss (12)
Women's health (1)
Worklife (1)
Date
Today (7)
Last 7 days (37)
Last 30 days (208)
Last 365 days (2555)
2025 (749)
2024 (2610)
2023 (2859)
2022 (3751)
2021 (4050)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1795)
2016 (1624)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1865)
Australia (298)
California (827)
Canada (132)
China (38)
Colorado (20)
Connecticut (10)
Delaware (4)
Europe (3818)
Florida (44)
Georgia (5)
Idaho (3)
Illinois (14)
India (1)
Indiana (32)
Japan (7)
Kansas (12)
Maryland (25)
Massachusetts (302)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (3)
New Hampshire (2)
New Jersey (69)
New York (49)
North Carolina (90)
Northern California (359)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (49)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (354)
Tennessee (2)
Texas (71)
Utah (2)
Virginia (6)
Washington D.C. (1)
Washington State (51)
Wisconsin (6)
38,192 Results for "sagimet biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
March 12, 2025
·
12 min read
Press Releases
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
March 12, 2025
·
6 min read
Press Releases
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
February 19, 2025
·
5 min read
Press Releases
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
January 6, 2025
·
5 min read
Business
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
Sagimet Biosciences Inc. announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.
May 6, 2024
·
7 min read
Press Releases
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
November 8, 2024
·
1 min read
Business
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2024, and provided recent corporate updates.
May 15, 2024
·
8 min read
Press Releases
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
·
1 min read
Drug Development
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT) today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
March 27, 2024
·
5 min read
Press Releases
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 14, 2024
·
10 min read
1 of 3,820
Next
